A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients

Chouinard, Guy; Jones, B.; Remington, Gary; M. Bloom, D.; Addington, Donald; William MacEwan, G.; Labelle, A.; Beauclair, Linda; Arnott, Wendy

doi:10.1097/00004714-199302000-00004

Public

A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients

Published in Journal of Clinical Psychopharmacology • Feb 1, 1993

Authors:

Guy Chouinard

B. Jones

Gary Remington

Abstract

In a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central 5-hydroxytryptamine2 and dopamine D2 antagonist), 2, 6, 10, 16 mg/day; haloperidol, 20 mg/day; or placebo, ...

Subject

Risperidone

Placebo

Haloperidol

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!